Characteristics of the studies included in the analysis
| Team | Knee OA cases/controls | Platform used | Age mean (range) | BMI mean (range) | Women (%) | Knee OA definition | Control definition |
|---|---|---|---|---|---|---|---|
| GWA studies | |||||||
| deCODE | 1033/32482 | Infinium HapMap 300 | 69 (19–99) | 26 (14–60) | 58 | TKR | Healthcare records |
| Framingham | 419/1674 | Affymetrix GeneChip | 64 (29–93) | 26 (14–54) | 56 | Radiographic | Radiographic |
| Rotterdam | 868/1464 | Illumina HapMap550v3 | 67 (55–94) | 26 (16–56) | 59 | Radiographic | Radiographic |
| TwinsUK | 51/289 | Infinium HapMap 300 | 54 (37–76) | 25 (15–51) | 100 | Radiographic | Radiographic |
| Replication cohorts: stage 1 | |||||||
| arcOGEN | 1643/4894 | Illumina 610 Quad | NA | NA | 71 | Radiographic/clinical | General population |
| Chingford* | 64/236 | NP | 63 (54–77) | 26 (17–43) | 100 | Radiographic | Radiographic |
| Finnish | 112/210 | NP | 67 (51–74) | 29 (20–42) | 75 | TKR | Population-based |
| Greek | 368/606 | NP | 61 (20–90) | 26 (17–34) | 72 | Clinical | Clinical |
| GARP | 161/758 | NP | 60 (30–79) | 27 (19–47) | 63 | Radiographic/clinical | Radiographic/clinical |
| Spanish | 262/294 | NP | 66 (32–94) | 31 (18–53) | TKR/clinical | Clinical | |
| Nottingham* | 647/237 | NP | 66 (40–97) | 27 (15–51) | 53 | TKR | Radiographic and clinical |
| Estonian | 69/456 | NP | 47 (32–60) | 28 (15–47) | 69 | Radiographic | Radiographic |
| Replication cohorts: stage 2 | |||||||
| deCODE | 622/32482† | Illumina and Centaurus (Nanogen) | 77 (40–99) | 29 (19–49) | 63 | TKR | Population-based |
| Swedish | 390/839 | NP | 62 (46–73) | 29 (18–51) | 63 | TKR+concomitant clinical and radiographic diagnosis of OA | General population without TKR |